US_outcomes_of_ORIENT-11_SuppTables.docx (28.48 kB)

Supplementary Tables – Generalizability of ORIENT-11 Trial Results to a US Standard of Care Cohort with Advanced Non-Small Cell Lung Cancer

dataset

posted on 2022-03-31, 07:56 authored by Figshare Future Science GroupFigshare Future Science Group, Nagasaka, Misako, Molife, Cliff, Cui, Zhanglin, Stefanik, Victoria, Li, Xiaohong, Kim, Sangmi, Lee, Hsiu-Yung, Beyrer, Julie, Blumenschein, G

Supplementary Table 1. Baseline Assessment between target US population and ORIENT-11 SPP and PPP arms before and after Adjustment^a

Abbreviations: BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; EB, entropy balancing; IPW, inverse probability weighting; N, number of patients in population; n, number of patients in the specified category; PPP, placebo+pemetrexed+platinum; PD-L1, programmed death-ligand 1; SD, standard deviation; SPP, sintilimab+pemetrexed+platinum; SMD, standardized mean difference between SPP and Target US Population or between PPP and Target US Population

* Data from Yang et al. 2020

^aAdjustment refers to IPW (primary analysis) and EB (sensitivity analysis)

^bAge was recorded at first line start date

^cDuration of disease was reported from advanced diagnosis to first line start date